Author Correction: Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth (Acta Pharmacologica Sinica, (2013), 34, 7, (930-938), 10.1038/aps.2013.40);Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth

Acta Pharmacologica Sinica

Volumn 34, Issue 7, 2013, Pages 930-938

  Qi, Qi ^a   Liu, Xia ^a   Li, Shiyong ^a   Joshi, Harish C ^a   Ye, Keqiang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; bis chloroethylnitrosourea; caspase 3; cisplatin; drug synergism; glioblastoma; noscapine; temozolamide; tumor xenograft model

Indexed keywords

CARMUSTINE; CASPASE 3; CISPLATIN; KI 67 ANTIGEN; NOSCAPINE; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GLIOBLASTOMA; GROWTH INHIBITORS; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; NOSCAPINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881441534     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/s41401-021-00762-w     Document Type: Erratum

References (34)

1. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci U S A 1998; 95: 1601-6.
2. Landen JW, Lang R, McMahon SJ, Rusan NM, Yvon AM, Adams AW, et al. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2002; 62: 4109-14.
3. Zhou J, Panda D, Landen JW, Wilson L, Joshi HC. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 2002; 277: 17200-8.
4. Zhou J, Gupta K, Yao J, Ye K, Panda D, Giannakakou P, et al. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 2002; 277: 39777-85.
5. Zhou J, Yao J, Joshi HC. Attachment and tension in the spindle assembly checkpoint. J Cell Sci 2002; 115: 3547-55.
6. Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, et al. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004; 10: 5187-201.
7. Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000; 49: 217-25.
8. Empey DW, Laitinen LA, Young GA, Bye CE, Hughes DT. Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol 1979; 16: 393-7.
9. Karlsson MO, Dahlstrom B, Eckernas SA, Johansson M, Alm AT. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol 1990; 39: 275-9.
10. Sammak PJ, Gorbsky GJ, Borisy GG. Microtubule dynamics in vivo: a test of mechanisms of turnover. J Cell Biol 1987; 104: 395-405.
11. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005; 5: 65-71.
12. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009; 8: 2086-95.
13. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996; 56: 2584-9.
14. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant betatubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118-25.
15. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1786-93.
16. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006; 69: 1801-9.
17. Sheleg SV, Korotkevich EA, Zhavrid EA, Muravskaya GV, Smeyanovich AF, Shanko YG, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol 2002; 60: 53-9.
18. Datta K, Babbar P, Srivastava T, Sinha S, Chattopadhyay P. p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. Int J Biochem Cell Biol 2002; 34: 148-57.
19. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
20. Newcomb EW, Lukyanov Y, Schnee T, Ali MA, Lan L, Zagzag D. Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug. Int J Oncol 2006; 28: 1121-30.
21. Mahmoudian M, Rahimi-Moghaddam P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov 2009; 4: 92-7.
22. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-81.
23. Newcomb EW, Lukyanov Y, Smirnova I, Schnee T, Zagzag D. Noscapine induces apoptosis in human glioma cells by an apoptosisinducing factor-dependent pathway. Anticancer Drugs 2008; 19: 553-63.
24. Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 2002; 21: 5038-46.
25. Jeong M, Kwon YS, Park SH, Kim CY, Jeun SS, Song KW, et al. Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PloS One 2009; 4: e4545.
26. Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S, Kondo S. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer 2003; 89: 922-9.
27. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999; 81: 1022-30.
28. Chen G, Pan QC. Potentiation of the antitumor activity of cisplatin in mice by 3-Aminobenzamide and nicotinamide. Cancer Chemother Pharmacol 1988; 22: 303-7.
29. Gilbert MR. New treatments for malignant gliomas: careful evaluation and cautious optimism required. Ann Intern Med 2006; 144: 371-3.
30. Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007; 67: 9809-16.
31. Barrie M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 2005; 16: 1177-84.
32. Altinoz MA, Bilir A, Del Maestro RF, Tuna S, Ozcan E, Gedikoglu G. Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro. Surg Neurol 2006; 65: 478-84.
33. Jhaveri N, Cho H, Torres S, Wang W, Schonthal AH, Petasis NA, et al. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 2011; 312: 245-52.
34. Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, et al. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer 2010; 46: 1668-78.